MARS is based on the application of the company's core patent "multi-physical configurable automatic separation" technology. Target cells were isolated from whole blood, monotherapy, and bone marrow samples using active acoustic microfluidics and magnetic separation techniques.

The installation sequence between functional modules can be freely combined to meet different customer requirements and allows customization in the overall workflow and each individual processing step. At the same time, through the control of the core device in the functional module, the target cells can be cleaned and concentrated.

The MARS platform not only ensures the value of specific cell integrity, high activity and high purity, but also perfectly meets the downstream needs of cell applications, such as cell culture and drug resistance testing, flow analysis, gene mutation detection and gene sequencing, etc., to meet the broad clinical and clinical research needs, and to achieve changes in the field of cell separation.